Zum Hauptinhalt springen

Naloxon

11. Januar 2026 | Naloxon

Drogennotfallprophylaxe - Neue Entwicklungen zu Take- Home-Naloxon

Drogennotfallprophylaxe - Neue Entwicklungen zu Take- Home-Naloxon Dirk Schäffer (Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.) und Simon Fleißner (Diese E-Mail-Adresse ist vor Spambots geschützt…

09. Januar 2026 | Naloxon

Effectiveness, acceptability, and feasibility of naloxone in carceral settings: a scoping review.

Effectiveness, acceptability, and feasibility of naloxone in carceral settings: a scoping review. Ravichandran N, Cullen W, Van Hout MC, Smyth J, Crowley D. Harm Reduct J. 2025 Nov 29. doi: 10.1186/s12954-025-01358-x. Epub ahead of pri…

28. Dezember 2025 | Naloxon

Post-marketing Surveillance of Intranasal Nalmefene: Prevalence and Clinical Relevance of Precipitated Withdrawal.

Post-marketing Surveillance of Intranasal Nalmefene: Prevalence and Clinical Relevance of Precipitated Withdrawal. Paavola J, Skolnick P, Wheeler A, Mankabady B, Laffont CM, Heidbreder C. Cureus. 2025 Oct 22;17(10):e95174. doi: 10.7759…

28. Dezember 2025 | Naloxon

Combining the alpha-2 adrenergic agonist clonidine with naloxone rescues fentanyl-induced physiologic dysfunction and increases survival.

Combining the alpha-2 adrenergic agonist clonidine with naloxone rescues fentanyl-induced physiologic dysfunction and increases survival. Rivera A, Schutzer WE, Sonneborn A, Shotwell SL, Janowsky A, Abbas AI, Torralva R. bioRxiv [Prepr…

28. Dezember 2025 | Naloxon

Is Fentanyl Rebound an Intrinsic Feature of Naloxone Reversal?

Is Fentanyl Rebound an Intrinsic Feature of Naloxone Reversal? Voronkov M, Nikonov G, Uzbil M, Milevich G, Abernethy J, Barthélémy I. Pharmaceuticals (Basel). 2025 Oct 29;18(11):1634. doi: 10.3390/ph18111634. PMID: 41304879; PMCID: PMC…

28. Dezember 2025 | Naloxon

Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids.

Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids. Nielsen S, Silva JP, Jones JD, Krotulski A, Poovendran D, Muzangizi D, Forte G, White J, Comer SD. Drug Alcohol Rev. 2026 Jan;45(1):e70040. doi: 10.1111/da…

28. Dezember 2025 | Naloxon

Use of low-threshold naloxone boxes for opioid overdose prevention in a Midwestern US State: a public health program evaluation.

Use of low-threshold naloxone boxes for opioid overdose prevention in a Midwestern US State: a public health program evaluation. Lynch PS, Gamalski L, Roys V, Albers A, Burk K, Durán S, Facente SN. Harm Reduct J. 2025 Nov 18;22(1):185…

Weitere
akutelle Informationen
zu den Themengebieten